Publication: Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
Loading...
Identifiers
Date
2022-09-16
Authors
Garcia-de-Lucas, Maria Dolores
Miramontes-Gonzalez, Jose Pablo
Aviles-Bueno, Beatriz
Jimenez-Millan, Ana Isabel
Rivas-Ruiz, Francisco
Perez-Belmonte, Luis M
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Research Foundation
Abstract
To investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals. An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting. The primary endpoint was the change in HbA1c from baseline to the end of the study. The secondary endpoints included changes in body weight and the proportion of people with T2DM, achieving HbA1c 5%. After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use.
Description
MeSH Terms
Adult
Ambulatory Care Facilities
Body Weight
Diabetes Mellitus, Type 2
Glucagon-Like Peptides
Glycated Hemoglobin
Humans
Hypoglycemic Agents
Retrospective Studies
Spain
Ambulatory Care Facilities
Body Weight
Diabetes Mellitus, Type 2
Glucagon-Like Peptides
Glycated Hemoglobin
Humans
Hypoglycemic Agents
Retrospective Studies
Spain
DeCS Terms
Peso corporal
Pacientes ambulatorios
España
Estudio clínico
Diabetes Mellitus tipo 2
Pacientes ambulatorios
España
Estudio clínico
Diabetes Mellitus tipo 2
CIE Terms
Keywords
HbA1c, T2DM, Body weight, Once-weekly semaglutide, Real-world use
Citation
Garcia de Lucas MD, Miramontes-González JP, Avilés-Bueno B, Jiménez-Millán AI, Rivas-Ruiz F, Pérez-Belmonte LM. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain. Front Endocrinol (Lausanne). 2022 Sep 16;13:995646